IDT Australia Limited (IDT) AI Stock Analysis

• Market Cap: AU$43.42M
• Dividend Yield: N/A
• Average Volume (3M): 123.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: 72.25%
• EPS Growth: 43.66%
• Country: AU
• Employees: 156
• Sector: Healthcare
• Sector Strength: 44
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 429,677,860
• 10 Day Avg. Volume: 94,009
• 30 Day Avg. Volume: 123,841
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

IDT Australia Limited's overall stock score reflects significant financial challenges, with ongoing losses and negative cash flow being the most critical issues. Technical analysis supports a neutral to slightly negative view, in line with the company's current financial state. The lack of a positive P/E and dividend yield further weighs on the stock's attractiveness.

IDT Australia Limited Business Overview & Revenue Model

Company Description

IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. It offers analytical method development, stability chambers, and chemistry and microbiology quality control laboratory services. The company also provides project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs, as well as pharmaceutical development services in various dosage forms. In addition, it offers medicinal cannabis products, as well as various contract manufacturing services. The company was founded in 1975 and is headquartered in Boronia, Australia.

How the Company Makes Money

IDT Australia Limited generates revenue primarily through the manufacturing and supply of pharmaceutical products. The company's key revenue streams include sales of active pharmaceutical ingredients (APIs) and finished dosage forms to pharmaceutical companies. Additionally, IDT provides contract manufacturing services, which involve producing pharmaceutical products on behalf of other companies. This includes both proprietary products developed by IDT and products manufactured under contract for third-party clients. The company may also engage in partnerships and collaborations with other pharmaceutical entities to expand its market reach and product offerings. Revenue growth is influenced by factors such as demand for pharmaceuticals, regulatory approvals, and the company's ability to secure manufacturing contracts.

IDT Australia Limited Financial Statement Overview

Summary

IDT Australia Limited faces substantial financial hurdles, with persistent losses and negative cash flow. While revenue growth is a positive sign, the company needs to address operational inefficiencies and improve cash management. The low leverage provides some stability, but enhancing profitability is crucial for future growth.

Income Statement

The income statement reveals a troubling trend in profitability. Despite revenue growth of 90.7% from 2023 to 2024, the company has consistently posted net losses, with a net profit margin of -40.9% in 2024. The gross profit margin improved to 50.7% in 2024, but negative EBIT and EBITDA margins suggest operational inefficiencies.

Balance Sheet

The balance sheet shows a moderate level of risk. The debt-to-equity ratio is 0.19, indicating low leverage, which is positive. However, stockholders' equity has decreased over the years, and the equity ratio stands at 74.7%. The company's total assets have grown, but there's a need to improve equity growth to support long-term stability.

Cash Flow

Cash flow analysis indicates significant challenges. The free cash flow in 2024 was deeply negative, showing a decline from 2023. The operating cash flow to net income ratio is negative, highlighting cash flow generation issues relative to reported losses.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
18.77M	13.23M	6.93M	12.11M	15.99M	14.10M
	Gross Profit
10.01M	10.42M	-3.53M	2.82M	4.88M	3.37M
	EBIT
-3.73M	-6.85M	-9.78M	-1.88M	966.00K	-1.28M
	EBITDA
-4.43M	-5.13M	-8.85M	-340.00K	2.75M	721.00K
	Net Income Common Stockholders
-4.80M	-5.41M	-8.50M	-1.16M	2.10M	-1.92M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.46M	904.00K	4.43M	9.21M	6.93M	6.86M
	Total Assets
37.60M	31.37M	28.29M	30.08M	34.13M	28.59M
	Total Debt
4.70M	4.47M	740.00K	881.00K	766.00K	5.00K
	Net Debt
3.64M	3.96M	-3.69M	-8.33M	-6.16M	-6.86M
	Total Liabilities
10.92M	7.93M	4.15M	3.46M	6.51M	5.29M
	Stockholders Equity
26.68M	23.44M	24.14M	26.63M	27.61M	23.30M
Cash Flow		Free Cash Flow
-11.86M	-10.30M	-8.42M	1.95M	-156.00K	-2.65M
	Operating Cash Flow
-10.70M	-9.60M	-7.90M	2.86M	370.00K	-1.89M
	Investing Cash Flow
-1.16M	-1.09M	-522.00K	-912.00K	-526.00K	-761.00K
	Financing Cash Flow
8.76M	6.77M	3.64M	337.00K	224.00K	12.00K

IDT Australia Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDT, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.08 is Neutral, neither overbought nor oversold. The STOCH value of 23.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IDT.

IDT Australia Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
IDT	44 Neutral	AU$43.42M	―	-19.31%	―	72.25%	43.66%
CMXHF		$76.87B	28.01	15.38%	1.73%	―	―
CYYNF		$25.67M	―	-75.39%	―	―	―
A1N		$3.71M	―	-67.69%	―	―	―
SPHRF		$24.75M	―	-43.63%	―	―	―
RCE	46 Neutral	AU$100.93M	―		―	―	-33.01%

IDT Australia Limited Corporate Events

IDT Australia Reports 30% Revenue Growth and Strong Contract Pipeline

IDT Australia Limited reported a 30% increase in quarterly revenue, reaching $4.1 million, driven by new contract wins and a strong pipeline of potential contracts totaling $62 million. The company experienced significant growth in its Active Pharmaceutical Ingredients vertical, which is expected to positively impact its Advanced Therapies and Specialty Orals segments. Despite global trade uncertainties, IDT’s outlook remains positive, with new contracts and proposals indicating robust future growth opportunities.

IDT Australia Director Increases Stake in Company

IDT Australia Limited announced a change in the director’s interest in securities, with Geoffrey Sam acquiring additional ordinary fully paid shares through on-market trades. This acquisition increases his total holdings, potentially signaling confidence in the company’s future performance and stability, which may positively impact stakeholder perception.

IDT Australia Secures $3.2M Contract for NPI-001 Manufacturing

IDT Australia Limited has secured a five-year, $3.2 million contract with Nacuity Pharmaceuticals for the manufacture of NPI-001, an investigational treatment for retinitis pigmentosa. This contract involves recommissioning IDT’s 4,000L Active Pharmaceutical Ingredient plant, making it the largest small molecule API facility in Australia, which strategically positions IDT to address potential drug shortages and expand its manufacturing capabilities.